NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
Business Wire•12/11/2026•16:05 ET
1
Key Highlights
- ➤2026 revenue guidance cut to $91 million-$92 million from $99.5 million-$101.5 million
- ➤Q3 total revenue $23.1 million, down 1.1% year over year
- ➤Q3 Adjusted EBITDA $0.4 million, improving from ($1.3) million
- ➤Remote Care PMA-Supplement submitted to FDA for planned 180-day review
- ➤Full-year Adjusted EBITDA guidance lowered to ($8.5) million-($9.5) million
Expert Statements
Joel Becker, President and Chief Executive Officer of NeuroPace
“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates,”
Joel Becker, President and Chief Executive Officer of NeuroPace
“The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“We are addressing these factors, and fourth-quarter scheduled cases have begun to recover.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Ongoing demand for RNS therapy, compelling clinical outcomes and the substantial opportunity within our current indication all remain and reinforce our confidence in the business performing in line with historical growth rates.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Our focus is on continuing to translate that opportunity into consistent growth through deeper customer engagement and stronger commercial execution.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized,”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Together with ECoG Assistant, our broader AI development programs and our next-generation platform, these initiatives can extend our reach to new patient populations and strengthen the differentiated value of RNS therapy.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“We believe the opportunity in our core business and the breadth of our pipeline position NeuroPace for substantial long-term growth.”
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
--Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth--
Get started
Create a free account to read the full story.